Literature DB >> 35062837

Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls.

Nathalie Mertens1, Laura Michiels2,3,4, Greet Vanderlinden1, Mathieu Vandenbulcke2,5, Robin Lemmens2,3,4, Koen Van Laere1,6, Michel Koole1.   

Abstract

[18F]MK-6240 is a second-generation tau PET-tracer to quantify neurofibrillary tangles in-vivo. However, individually variable levels of meningeal uptake induce spill-in-effects into the cortex, complicating [18F]MK-6240 PET quantification. Group SUVR differences between age-matched HC subgroups with varying extracerebral uptake (EC-low/mixed/high), and between aMCI and each HC subgroup were assessed without and with partial volume correction (PVC). Both Müller-Gartner (MG-)PVC and region-based voxelwise (RBV-)PVC, with the latter also correcting for extracerebral spill-in-effects, were implemented. Between HC groups, where no differences are to be expected, HC EC-high showed spill-in differences compared to HC EC-low when no PVC was applied while for MG-PVC, differences were reduced and, for RBV-PVC, no statistically significant differences were observed. Between aMCI and HC, cortical SUVR differences were statistically significant, both without and with PVC, but modulated by the varying meningeal uptake in HC subgroups when no PVC was applied. After applying PVC, correlations to clinical parameters improved and effect sizes between HC and aMCI increased, independent of the HC-subgroup. Therefore, appropriate PVC with correction for extracerebral spill-in-effects is recommended to minimize the impact of varying meningeal uptake on cortical differences between HC and aMCI.

Entities:  

Keywords:  [18F]MK-6240 PET quantification; amnestic mild cognitive impairment; healthy controls; meningeal uptake; partial volume correction

Mesh:

Substances:

Year:  2022        PMID: 35062837      PMCID: PMC9207493          DOI: 10.1177/0271678X221076023

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.960


  31 in total

1.  Automatically parcellating the human cerebral cortex.

Authors:  Bruce Fischl; André van der Kouwe; Christophe Destrieux; Eric Halgren; Florent Ségonne; David H Salat; Evelina Busa; Larry J Seidman; Jill Goldstein; David Kennedy; Verne Caviness; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Cereb Cortex       Date:  2004-01       Impact factor: 5.357

2.  Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects.

Authors:  H W Müller-Gärtner; J M Links; J L Prince; R N Bryan; E McVeigh; J P Leal; C Davatzikos; J J Frost
Journal:  J Cereb Blood Flow Metab       Date:  1992-07       Impact factor: 6.200

3.  Tau PET in Alzheimer disease and mild cognitive impairment.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; Jae Hoon Lee; You Jin Kim; Hye Mi Lee; Chul Hyoung Lyoo; Young Hoon Ryu; Myung Sik Lee
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

4.  What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies.

Authors:  Victor L Villemagne; Brian J Lopresti; Vincent Doré; Dana Tudorascu; Milos D Ikonomovic; Samantha Burnham; Davneet Minhas; Tharick A Pascoal; N Scott Mason; Beth Snitz; Howard Aizenstein; Chester A Mathis; Oscar Lopez; Christopher C Rowe; William E Klunk; Ann D Cohen
Journal:  J Nucl Med       Date:  2020-12-31       Impact factor: 10.057

5.  In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment.

Authors:  Heleen Vanhaute; Jenny Ceccarini; Laura Michiels; Michel Koole; Stefan Sunaert; Robin Lemmens; Eric Triau; Louise Emsell; Mathieu Vandenbulcke; Koen Van Laere
Journal:  Neurology       Date:  2020-06-03       Impact factor: 9.910

6.  Test-retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer's disease.

Authors:  Cristian Salinas; Talakad G Lohith; Ajay Purohit; Arie Struyk; Cyrille Sur; Idriss Bennacef; John Beaver; Laurent Martarello
Journal:  J Cereb Blood Flow Metab       Date:  2019-11-11       Impact factor: 6.200

7.  Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site.

Authors:  Tetsuro Tago; Jun Toyohara; Ryuichi Harada; Shozo Furumoto; Nubuyuki Okamura; Yukitsuka Kudo; Junko Takahashi-Fujigasaki; Shigeo Murayama; Kenji Ishii
Journal:  Ann Nucl Med       Date:  2019-02-22       Impact factor: 2.668

8.  Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects.

Authors:  Nicolas J Guehl; Dustin W Wooten; Daniel L Yokell; Sung-Hyun Moon; Maeva Dhaynaut; Samantha Katz; Kirsten A Moody; Codi Gharagouzloo; Aurélie Kas; Keith A Johnson; Georges El Fakhri; Marc D Normandin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-22       Impact factor: 9.236

9.  Attenuation correction synthesis for hybrid PET-MR scanners: application to brain studies.

Authors:  Ninon Burgos; M Jorge Cardoso; Kris Thielemans; Marc Modat; Stefano Pedemonte; John Dickson; Anna Barnes; Rebekah Ahmed; Colin J Mahoney; Jonathan M Schott; John S Duncan; David Atkinson; Simon R Arridge; Brian F Hutton; Sebastien Ourselin
Journal:  IEEE Trans Med Imaging       Date:  2014-07-17       Impact factor: 10.048

10.  Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948.

Authors:  Ruben Smith; Michael Schöll; Antoine Leuzy; Jonas Jögi; Tomas Ohlsson; Olof Strandberg; Oskar Hansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-14       Impact factor: 9.236

View more
  1 in total

1.  Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern.

Authors:  Greet Vanderlinden; Jenny Ceccarini; Thomas Vande Casteele; Laura Michiels; Robin Lemmens; Eric Triau; Kim Serdons; Jos Tournoy; Michel Koole; Mathieu Vandenbulcke; Koen Van Laere
Journal:  Mol Psychiatry       Date:  2022-07-06       Impact factor: 15.992

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.